论文部分内容阅读
过继性输注肿瘤浸润性淋巴细胞(TILs)能可靠地治疗转移性黑色素瘤,并使其有效率稳定在50%左右。但由于受TIL来源的限制,大多数非黑色素瘤病人无法使用过继性免疫治疗。使用抗肿瘤抗原TCR修饰的T淋巴细胞成功用于黑色素瘤病人的治疗为非黑色素瘤癌症病人的过继性免疫治疗提供了方向。本综述介绍了近几年来肿瘤特异性过继免疫治疗的进展,重点介绍基因修饰的T淋巴细胞的应用及存在的问题,并展望了发展前景。
Adoptive infusion of tumor-infiltrating lymphocytes (TILs) reliably treats metastatic melanoma and stabilizes it to around 50%. However, due to the limitations of TIL sources, most non-melanoma patients are unable to use adoptive immunotherapy. The successful use of T lymphocytes modified with the anti-tumor antigen TCR for the treatment of melanoma patients provides an orientation for adoptive immunotherapy of non-melanoma cancer patients. This review presents the progress of tumor-specific adoptive immunotherapy in recent years, highlighting the applications and problems of genetically modified T lymphocytes and prospects for future development.